ϳ1.3 mmol/L. In 0.129 mol/L citrate samples, the mean Ca 2ϩ concentration in the reaction mixture was 0.21 mmol/L (14%) lower than the concentration in 0.109 mol/L citrate samples, using the Quick method. The difference in Ca 2ϩ concentrations is the same with other Quick reagents because the relationship between the volumes (50 L ϩ 100 L) in the reaction mixture is the same with every reagent. The influence of variable Ca 2ϩ concentrations in the reaction mixture can exert different effects on the results obtained with different Quick reagents and thromboplastins.
concentrations in the reaction mixture can exert different effects on the results obtained with different Quick reagents and thromboplastins.
In addition, in the Quick method, the Ca 2ϩ concentration varies widely (1.07-1.79 mmol/L in 0.129 mol/L citrate samples), and the CV is 13%. In the 0.129 mol/L reaction mixtures, in 5 of 30 samples, the Ca 2ϩ concentration was Ͻ1.3 mmol/L. When 0.109 mol/L citrate samples were used in the Quick method, the lowest Ca 2ϩ concentration in the reaction mixture was 1.3 mmol. The Ca 2ϩ concentrations in the coagulation mixtures are clearly different between two sample citrate concentrations with the Quick method.
When a sample is diluted (1 ϩ 9) with citrate solution, the dilution occurs in plasma, not in whole blood, and depending on the hematocrit, the plasma volume will differ from sample to sample. The situation is similar if too little blood is drawn into the collection tube and the tube is underfilled. The Ca 2ϩ concentration in patient plasma can sometimes be low. The citrate concentration is markedly variable in plasma, as well as in the coagulation reaction mixture in the Quick method.
Because the Ca 2ϩ concentration is lower in 0.129 mol/L citrate samples, the times for PT coagulation and activated partial thromboplastin time measurements are longer than the corresponding times for patient samples containing 0.109 mol/L citrate for patient groups designated as "no anticoagulant therapy" and "anticoagulant therapy" when PT (ISI, 1.0; Quick method) and activated partial thromboplastin time reagents are used (9 ). Duncan et al. (8 ) showed that the concentration of citrate in the sample affects the results and ISI calibration (Quick methods). The citrate concentration exerts an ϳ10% effect on the ISI of reagents. The above-mentioned results of two studies agree well with the PT and calcium results in our study.
With Owren's PT, the mean difference in the Ca 2ϩ concentration in the reaction mixture was 0.01 mmol/L (0.4%) and the CVs were 4.9% for 0.129 mol/L citrate and 3.0% for 0.109 mol/L. The sample citrate concentration has no effect on the Owren method, and this method is also less sensitive to other preanalytical variables by reason of the small sample volume (5%) in the reaction mixture. Because the Owren and Quick methods depend differently on sample citrate concentrations (Ca 2ϩ in the reaction mixture), the correlation is not so good.
We subscribe to the demand for unification of recommendations of a sample citrate concentration of 0.109 mol/L to improve results for PT and activated partial thromboplastin times (8, 9 It has been suggested that the hexosamine biosynthetic pathway is involved in the pathogenesis of insulin resistance in patients with type 2 diabetes mellitus because the activity of the rate-limiting enzyme of this pathway, glutamine:fructose-6-phosphate amidotransferase (EC 2.6.1.16), is increased in skeletal muscle of patients with type 2 diabetes mellitus (1 ). In rats, the skeletal muscle concentrations of the major end products of this pathway, i.e., UDP-N-acetylgalactosamine (UDP-GalNAc) and UDP-N-acetylglucosamine (UDP-GlcNAc), are highly correlated with the degree of insulin resistance (2 ) . HPLCbased methods have been applied to measure UDPhexosamines in rat or murine tissues (2) (3) (4) (5) (6) (7) . In contrast to capillary zone electrophoresis (8, 9 ) , these methods are reportedly not sensitive enough to measure hexosamines in small samples of tissue, and most are not able to separate the glucose-galactose epimers of UDP-hexosamines and UDP-hexoses (9 ) .
For our studies into the role of the hexosamine pathway in type 2 diabetes mellitus, we were interested in a method to assess UDP-galactose (UDP-Gal), UDP-glucose (UDP-Glc), UDP-GalNAc, and UDP-GlcNAc in small samples of human muscle tissue, e.g., percutaneous muscle biopsies. To this end, we optimized and characterized an HPLC-based assay (5 ). The assay was suitable for application in small samples of human muscle tissue (Ͼ30 mg) and separated all of the above-mentioned analytes of interest.
Human muscle tissue (musculus gluteus maximus) was obtained from 17 patients during hip replacement surgery, after approval by the institutional human research committee and after informed consent. Twelve patients (6 females and 6 males) were normoglycemic with hemoglobin A 1c values of 4.4 -5.9%. Five patients (four females and one male) were diabetic, with hemoglobin A 1c values of 7.2-9.6%. Tissues were homogenized with homogenization buffer (100 mmol/L KCl, 1 mmol/L EDTA, 50 mmol/L KH 2 PO 4 , pH 7.5; 5 mL of buffer/g of tissue) in a dismembrator (45 s at highest setting; Braun) using liquid nitrogen. For optimization and characterization of the assay, a pool of eight muscle tissues from normoglycemic patients was used. After centrifugation at 60 000g for 15 min at 4°C, 1600 pmol of UDP-mannose and 25 pmol of UDP-xylose were added to the supernatant as internal standards. For recovery studies, known amounts were added at this time. The samples were deproteinized by addition of 1 volume of 1.2 mol/L perchloric acid and subsequent centrifugation for 10 min at 13 500g at 4°C. The resulting supernatants, diluted with 10 volumes of 10 mmol/L KH 2 PO 4 (pH 2.5), were applied to 3-mL Supelclean LC-SAX solid-phase extraction columns (Supelco). After the columns were washed with 5 mL of 10 mmol/L KH 2 PO 4 (pH 2.5), 2.5 mL of 50 mmol/L KH 2 PO 4 (pH 2.5), and 0.5 mL of 150 mmol/L KH 2 PO 4 (pH 7.5) consecutively, the UDP-sugars were eluted with 1.5 mL of 150 mmol/L KH 2 PO 4 (pH 7.5). Samples (150 L) were injected using a 717plus Autosampler (Waters Chromatography). UDP-sugars were separated and quantified by HPLC (Waters), using two LC-18T columns in series [25 cm ϫ 4.6 mm (i.d.); 5 m bead size; Supelco] and ultraviolet detection at 262 nm (2487 Dual Absorbance Detector; Waters). The mobile phase, at a flow of 1 mL/min, was a 0.1 mol/L KH 2 PO 4 buffer containing 2 mmol/L tetrabutylammonium phosphate, pH 6.2. Before and after each set of runs, three calibrators of all UDPsugars to be quantified were analyzed at 0.1, 0.5, and 1.0 mol/L. All unknowns were quantified using these calibration curves. All values are shown as nanomoles per milliliter of injected sample, and individual samples are normalized for tissue wet weight.
All metabolites of interest and the internal standards demonstrated baseline separation (Fig. 1) . The specificity of the assay was analyzed using a 996 Photo-Diode Array Detector (Waters); it revealed no discernible interfering substances and confirmed the purities and identities of the analytes of interest.
Known amounts at six concentrations ranging from 25% to 4000% of the endogenous concentrations of UDPsugars were added to a 30-mg (wet weight) equivalent of pooled muscle tissue. Measurements of these samples were replicated five times per concentration on different days. Recoveries of added substances and internal standards were 88 -109%, without any obvious correlation with concentrations.
The assay was linear over the entire range measured. Linear regression analysis of measured amounts (y; corrected for endogenous concentrations) vs added amounts Table 1 . Even in a muscle tissue equivalent as low as 15 mg (wet weight), CVs were Յ13% for all UDP-sugars. Intraassay CVs at endogenous concentrations in a 30-mg tissue sample are shown in Table 1 .
The limit of detection, defined as 3 times the SD of the background signal, and the limit of quantification, defined as 10 times the SD, were 0.04 and 0.125 nmol/mL of homogenate, respectively. This limit of quantification was equivalent to 0.625 nmol/g of tissue (wet weight). Considering the amounts of UDP-sugars found in the pooled Fig. 1 . HPLC elution profile of UDP-sugars.
UDP-mannose and UDP-xylose were added as internal standards. A typical HPLC profile of endogenous UDP-Gal, UDP-Glc, UDP-GalNAc, and UDP-GlcNAc in a 30-mg (wet weight) equivalent human muscle tissue pool is shown. muscle tissues, a minimum of 37, 13, 32, and 20 mg of tissue (wet weight) would be sufficient to accurately quantify UDP-Gal, UDP-Glc, UDP-GalNAc, and UDPGlcNAc, respectively.
Aliquots of muscle homogenate could be kept at Ϫ80°C for at least 3 months, and freeze-thawing of the muscle homogenate pool did not lead to diminished concentrations of UDP-sugars. The fractions obtained after strong ion-exchange chromatography could be kept at room temperature overnight without degradation.
In 12 normoglycemic subjects the following concentrations, mean (SD), of UDP-sugars were found: UDP-Gal, (1.96) nmol/g of tissue; P Ͼ0.1 for both compared with concentrations in normoglycemic subjects]. These preliminary data on UDP-hexose and UDP-hexosamine concentrations in human skeletal muscle differ from earlier studies performed in rats and mice (2) (3) (4) (5) (6) (7) .
In contrast to most reported HPLC-based assays (3, 6, 7 ) , all hexosamine biosynthesis pathway metabolites of interest are separated in this method. The method is sensitive enough to accurately quantify UDP-hexoses and UDP-hexosamines in small samples of human skeletal muscle, e.g., those obtained by percutaneous muscle biopsy. We currently are collecting muscle tissue from a large number of diabetics and controls to confirm and extend the preliminary data described here. Hepatic enzymes in serum, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), are routinely measured in serum for the diagnosis of hepatic disease; however, these enzymes are not liver specific because they are widely distributed in nonhepatic tissues. In contrast, urea cycle enzymes, i.e., liver-type arginase (ARG), ornithine carbamoyltransferase (OCT), and argininosuccinate synthase (AS), exist almost exclusively in the liver (1-3 ) and may serve as more specific markers of liver 
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